Physician profile
Atiya S Khan
NPI 1881691368
$1,203,578.16
in general payments reported to CMS, 2019-2025
42 companies · $242K in 2025
The $242K reported for 2025 was more than what 99% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $48K · 2021: $131K · 2022: $210K · 2023: $174K · 2024: $235K · 2025: $242K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $482K · Honoraria: $83K · Travel and Lodging: $52K · Food and Beverage: $24K · Consulting Fee: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $481,965.00 |
| Honoraria | $83,013.50 |
| Travel and Lodging | $52,196.15 |
| Food and Beverage | $23,683.92 |
| Consulting Fee | $10,240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $348,232.51 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $243,573.70 | 2020-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $200,935.90 | 2019-2025 | Epidiolex |
| Eisai INC. | $155,298.78 | 2019-2023 | |
| Sk Life Science, INC. | $84,784.64 | 2020-2025 | Xcopri |
| Catalyst Pharmaceuticals, INC. | $70,754.81 | 2023-2025 | Fycompa, Firdapse |
| Greenwich Biosciences, INC. | $46,706.22 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $28,256.62 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $10,002.92 | 2019-2020 | |
| Livanova USA, INC. | $9,543.18 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biocodex, INC. | $2,564.94 | 2023-2025 | Diacomit |
| Acadia Pharmaceuticals INC | $449.35 | 2023-2025 | Daybue |
| Ptc Therapeutics, INC. | $299.33 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $290.04 | 2019-2020 | |
| Abbvie INC. | $217.09 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atiya Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.